Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial

Adjuvant Tamoxifen ◽

Therapeutic Drug ◽

Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients‐A Cost‐effectiveness analysis

Journal of Gastroenterology and Hepatology ◽

10.1111/jgh.15373 ◽

2020 ◽

Cited By ~ 1

Author(s):

Jiaqi Yao ◽

Xinchan Jiang ◽

Joyce H.S. You

Keyword(s):

Crohn’S Disease ◽

Cost Effectiveness ◽

Therapeutic Drug Monitoring ◽

Crohn's Disease ◽

Drug Monitoring ◽

Therapeutic Drug ◽

PHS43 Cost-Effectiveness Analysis of Therapeutic Drug Monitoring in Pediatric Patients Diagnosed With Structural-Metabolic Epilepsy

Value in Health ◽

10.1016/j.jval.2012.08.1816 ◽

2012 ◽

Vol 15 (7) ◽

pp. A525

Author(s):

M.R.M. Salih ◽

M.B. Bahari ◽

A.A. Shafie ◽

M.A. Ahmad hassali ◽

O.Q.B. Al-lela ◽

...

Keyword(s):

Cost Effectiveness ◽

Therapeutic Drug Monitoring ◽

Drug Monitoring ◽

Pediatric Patients ◽

Therapeutic Drug ◽

Effectiveness Analysis ◽

Metabolic Epilepsy

58P Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.03.072 ◽

2021 ◽

Vol 32 ◽

pp. S45

Author(s):

X. Guan ◽

H-C. Li ◽

Q-J. Chen ◽

B. Hua ◽

J-J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1909478 ◽

2021 ◽

pp. 1-10

Author(s):

Carlos Henrique Botelho ◽

Maria Del Pilar Estevez-Diz ◽

Alessandro Gonçalves Campolina

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

Value in Health ◽

10.1016/j.jval.2019.09.048 ◽

2019 ◽

Vol 22 ◽

pp. S405-S406

Author(s):

X. Guan ◽

H. Li ◽

Q. Chen ◽

C. Hao ◽

J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

High Risk ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Her2 Positive ◽

Risk Of Recurrence ◽

Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China

Clinical Drug Investigation ◽

10.1007/s40261-019-00842-0 ◽

2019 ◽

Vol 40 (1) ◽

pp. 25-32 ◽

Cited By ~ 2

Author(s):

Xiaoxia Wei ◽

Hong Sun ◽

Jie Zhuang ◽

Xiuhua Weng ◽

Bin Zheng ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Pharmacogenetic Testing ◽

Effectiveness Analysis ◽

Estrogen Receptor Positive

Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective

PLoS ONE ◽

10.1371/journal.pone.0172731 ◽

2017 ◽

Vol 12 (3) ◽

pp. e0172731 ◽

Cited By ~ 6

Author(s):

Caroline S. Clarke ◽

Rachael M. Hunter ◽

Ian Shemilt ◽

Victoria Serra-Sastre

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Trastuzumab ◽

Effectiveness Analysis ◽

Payer Perspective

Cost Effectiveness Analysis of Targeted Intraoperative Radiotherapy Alone (TARGIT-A) in Early Breast Cancer Patients

Value in Health ◽

10.1016/j.jval.2014.08.2306 ◽

2014 ◽

Vol 17 (7) ◽

pp. A640 ◽

Cited By ~ 3

Author(s):

A. Vaidya ◽

P. Vaidya ◽

B. Both ◽

C. Brew-Graves ◽

J. Vaidya

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Early Breast Cancer ◽

Intraoperative Radiotherapy ◽

Breast Cancer Patients ◽

Effectiveness Analysis ◽

Radiotherapy Alone

Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer

PharmacoEconomics ◽

10.2165/11588340-000000000-00000 ◽

2011 ◽

Vol 29 (5) ◽

pp. 415-432 ◽

Cited By ~ 36

Author(s):

Peter S. Hall ◽

Claire Hulme ◽

Christopher McCabe ◽

Yemi Oluboyede ◽

Jeff Round ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

Value in Health ◽

10.1016/s1098-3015(10)68918-8 ◽

2007 ◽

Vol 10 (3) ◽

pp. A125 ◽

Cited By ~ 1

Author(s):

E Orlewska ◽

T Pienkowski ◽

K Drosik ◽

M Gyldmark ◽

R Aultman ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Early Breast Cancer ◽

Her2 Positive ◽